Cargando…
PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars
BACKGROUND: With the introduction of tumor necrosis factor (TNF) alpha inhibitors, the treatment of inflammatory rheumatic diseases (IRD) has undergone a fundamental change. Several of the originally high-priced biologics are now accessible as lower cost biosimilars, removing a significant impedimen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Medizin
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627965/ https://www.ncbi.nlm.nih.gov/pubmed/36006471 http://dx.doi.org/10.1007/s00393-022-01259-5 |
_version_ | 1785131647576834048 |
---|---|
author | Hörbrand, Franziska Schuch, Florian Bleß, Hans-Holger Messinger, David Bretthauer, Bork Killian, Peter |
author_facet | Hörbrand, Franziska Schuch, Florian Bleß, Hans-Holger Messinger, David Bretthauer, Bork Killian, Peter |
author_sort | Hörbrand, Franziska |
collection | PubMed |
description | BACKGROUND: With the introduction of tumor necrosis factor (TNF) alpha inhibitors, the treatment of inflammatory rheumatic diseases (IRD) has undergone a fundamental change. Several of the originally high-priced biologics are now accessible as lower cost biosimilars, removing a significant impediment to prescription. OBJECTIVE: The present study investigated whether the availability of biosimilars is associated with an improvement in the care of IRD. Moreover, the subjective acceptance of biosimilars by physicians and patients was investigated and compared with objectifiable parameters. MATERIAL AND METHODS: Pseudonymized claims data of the Bavarian Association of Statutory Health Insurance Physicians from 2014 to 2019 as well as a paper and pencil survey of patients and rheumatologists formed the data basis of the study. RESULTS: During the observation period, the proportion of diagnosed patients receiving drug therapy increased from 38.5% to 43.2%. Also, the care changed in terms of the prescribed agents. Conventional drug therapy declined overall and, in particular, glucocorticoid prescriptions decreased from 39.3% in 2014 to 34.3% in 2019. At the same time, the proportion of targeted treatments increased from 12.3% to 20.4%. The median duration of basic treatment before first-time bDMARD use dropped from 3.15 years in 2014 to 2.17 years in 2019. CONCLUSION: Over the observation period, in which three biosimilars entered the market, the care of patients with IRD improved both quantitatively and qualitatively. The market share of biosimilars increased in parallel with this development. With an overall high acceptance of biosimilars, the assessment of the disease course by physicians and patients indicates a slight subjectively perceived advantage of therapy with originals compared to biosimilars, which, however, is not confirmed when standardized scores are applied. A possible explanation for this might be a nocebo effect, which could be minimized by suitable communication strategies. |
format | Online Article Text |
id | pubmed-10627965 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Medizin |
record_format | MEDLINE/PubMed |
spelling | pubmed-106279652023-11-08 PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars Hörbrand, Franziska Schuch, Florian Bleß, Hans-Holger Messinger, David Bretthauer, Bork Killian, Peter Z Rheumatol Versorgung BACKGROUND: With the introduction of tumor necrosis factor (TNF) alpha inhibitors, the treatment of inflammatory rheumatic diseases (IRD) has undergone a fundamental change. Several of the originally high-priced biologics are now accessible as lower cost biosimilars, removing a significant impediment to prescription. OBJECTIVE: The present study investigated whether the availability of biosimilars is associated with an improvement in the care of IRD. Moreover, the subjective acceptance of biosimilars by physicians and patients was investigated and compared with objectifiable parameters. MATERIAL AND METHODS: Pseudonymized claims data of the Bavarian Association of Statutory Health Insurance Physicians from 2014 to 2019 as well as a paper and pencil survey of patients and rheumatologists formed the data basis of the study. RESULTS: During the observation period, the proportion of diagnosed patients receiving drug therapy increased from 38.5% to 43.2%. Also, the care changed in terms of the prescribed agents. Conventional drug therapy declined overall and, in particular, glucocorticoid prescriptions decreased from 39.3% in 2014 to 34.3% in 2019. At the same time, the proportion of targeted treatments increased from 12.3% to 20.4%. The median duration of basic treatment before first-time bDMARD use dropped from 3.15 years in 2014 to 2.17 years in 2019. CONCLUSION: Over the observation period, in which three biosimilars entered the market, the care of patients with IRD improved both quantitatively and qualitatively. The market share of biosimilars increased in parallel with this development. With an overall high acceptance of biosimilars, the assessment of the disease course by physicians and patients indicates a slight subjectively perceived advantage of therapy with originals compared to biosimilars, which, however, is not confirmed when standardized scores are applied. A possible explanation for this might be a nocebo effect, which could be minimized by suitable communication strategies. Springer Medizin 2022-08-25 2023 /pmc/articles/PMC10627965/ /pubmed/36006471 http://dx.doi.org/10.1007/s00393-022-01259-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Versorgung Hörbrand, Franziska Schuch, Florian Bleß, Hans-Holger Messinger, David Bretthauer, Bork Killian, Peter PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars |
title | PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars |
title_full | PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars |
title_fullStr | PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars |
title_full_unstemmed | PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars |
title_short | PHARAO-Studie: Arzneimittelversorgung entzündlich rheumatischer Erkrankungen: Leitliniengerechte Versorgung mit Biologika folgt Verfügbarkeit von Biosimilars |
title_sort | pharao-studie: arzneimittelversorgung entzündlich rheumatischer erkrankungen: leitliniengerechte versorgung mit biologika folgt verfügbarkeit von biosimilars |
topic | Versorgung |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627965/ https://www.ncbi.nlm.nih.gov/pubmed/36006471 http://dx.doi.org/10.1007/s00393-022-01259-5 |
work_keys_str_mv | AT horbrandfranziska pharaostudiearzneimittelversorgungentzundlichrheumatischererkrankungenleitliniengerechteversorgungmitbiologikafolgtverfugbarkeitvonbiosimilars AT schuchflorian pharaostudiearzneimittelversorgungentzundlichrheumatischererkrankungenleitliniengerechteversorgungmitbiologikafolgtverfugbarkeitvonbiosimilars AT bleßhansholger pharaostudiearzneimittelversorgungentzundlichrheumatischererkrankungenleitliniengerechteversorgungmitbiologikafolgtverfugbarkeitvonbiosimilars AT messingerdavid pharaostudiearzneimittelversorgungentzundlichrheumatischererkrankungenleitliniengerechteversorgungmitbiologikafolgtverfugbarkeitvonbiosimilars AT bretthauerbork pharaostudiearzneimittelversorgungentzundlichrheumatischererkrankungenleitliniengerechteversorgungmitbiologikafolgtverfugbarkeitvonbiosimilars AT killianpeter pharaostudiearzneimittelversorgungentzundlichrheumatischererkrankungenleitliniengerechteversorgungmitbiologikafolgtverfugbarkeitvonbiosimilars |